--- title: "Weekly Recap | WUXI BIO +10.49%, closing in on record highs" type: "News" locale: "en" url: "https://longbridge.com/en/news/296665656.md" description: "WUXI BIO (2269.HK) rallied 10.49% this week to close at HK$51, outpacing the Hang Seng Index’s 2.19% gain by roughly 8.3 percentage points. Over the four trading days, the stock carved out a push-pull-resume pattern: Monday (17 Aug) opened at HK$46.28 and surged nearly 5% on heavy volume; Tuesday (18 Aug) saw a mild pullback to HK$47.90; Wednesday (19 Aug) gapped higher to HK$51.50, touching a 60-day high of HK$51.55 before fading to HK$49." datetime: "2026-08-22T04:08:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296665656.md) - [en](https://longbridge.com/en/news/296665656.md) - [zh-HK](https://longbridge.com/zh-HK/news/296665656.md) generator: "portal-rs" --- # Weekly Recap | WUXI BIO +10.49%, closing in on record highs ## The Week WUXI BIO (2269.HK) rallied 10.49% this week to close at HK$51, outpacing the Hang Seng Index’s 2.19% gain by roughly 8.3 percentage points. Over the four trading days, the stock carved out a push-pull-resume pattern: Monday (17 Aug) opened at HK$46.28 and surged nearly 5% on heavy volume; Tuesday (18 Aug) saw a mild pullback to HK$47.90; Wednesday (19 Aug) gapped higher to HK$51.50, touching a 60-day high of HK$51.55 before fading to HK$49.64; Thursday (20 Aug) reclaimed momentum and closed at the session high of HK$51. Average daily volume ran about 47% above the 60-day median. ## Key Events The wider CXO sector caught a bid this week, lifting WUXI BIO to a 52-week high as early as Tuesday. On the same day, the company was recognised on the 2026 BioPharma APAC sustainable biopharma list and named a top industry performer for sustainable practices — a quiet signal on the ESG front that complemented the price action. Thursday brought a sharper catalyst: reports of an mRNA vaccine breakthrough sent the stock up more than 7% at the open, marking another 52-week high. The move rippled through Hong Kong’s innovative-drug space, with peers like WuXi AppTec and BeiGene also hitting fresh highs during the session, reflecting a broad pickup in risk appetite for the biopharma sector. ## Analyst Ratings A total of 25 brokers cover WUXI BIO: 16 rate it buy, 4 rate it overweight, and 5 rate it hold, with no sell or underweight ratings. The consensus recommendation is buy, with a consensus target price of about HK$47.53. With the stock closing the week at HK$51, the price now sits roughly 6.8% above that consensus target. The target range is wide — from a low of HK$30.75 to a high of HK$78.85 — suggesting significant disagreement on the company’s long-term valuation. WUXI BIO ranks first by analyst coverage within its life-sciences tools and services peer group. ## The Week Ahead WUXI BIO is set to report its fiscal-first-half 2026 results on Tuesday (25 Aug), with the market pencilling in revenue of around HK$13.3 billion. The stock has already priced in a fair amount of optimism this week; the actual numbers and management’s second-half outlook will be the real test of whether the rally has legs. ## In Short WUXI BIO staged a high-volume breakout this week, fuelled by sector rotation and the mRNA vaccine narrative. The ratings backdrop is broadly favourable, though the stock has already edged past the consensus target price, and the wide spread of broker targets points to a genuine valuation debate. In the latest session, large-lot money was a net seller while medium and small orders were net buyers. The half-year report next week is the next checkpoint — markets will want to see whether the fundamentals can back up the current multiple. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [02269.HK](https://longbridge.com/en/quote/02269.HK.md) ## Related News & Research - [WuXi Biologics (Cayman) (SEHK:2269) Shares Climbed, So What Is Driving Attention Now?](https://longbridge.com/en/news/296943664.md) - [Wuxi Biologics ADR Non-GAAP EPS of RMB0.81, revenue of RMB11.78B](https://longbridge.com/en/news/296950743.md) - [WUXI APPTEC Reportedly Sells 2.6% Stake in WUXI XDC for Up to HKD2.4B](https://longbridge.com/en/news/297110148.md) - [Transcenta Holding announces extraordinary general meeting](https://longbridge.com/en/news/296833106.md) - [CStone plans first wave of global Phase III trials for CS2009 by end-2026](https://longbridge.com/en/news/297516705.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**